Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
daptomycin
Merck Sharp & Dohme B.V.
J01XX09
daptomycin
Antibacterials for systemic use,
Gram-Positive Bacterial Infections; Bacteremia; Soft Tissue Infections; Endocarditis, Bacterial
Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Revision: 37
Authorised
2006-01-19
1 ANNEX I SUMMARY OF PRODUCT C HARA CTERISTICS 2 1. NAME OF THE MEDI CINAL PRODUCT Cubicin 350 mg powder for solution for injection or infusion Cubicin 500 mg powder for solution for in jection or infusion 2. QUALIT ATIVE AND QUANTITATI VE COMPOSITION Cubicin 350 mg powder for solution for i njection or infusion Each vial contains 350 mg daptomycin. One ml provid es 50 mg of dapt omycin after reconstitution with 7 ml of sodium chloride 9 mg/ml (0.9 %) solution. Cubicin 500 mg powder for so lution for injection or infusion Each vial contains 500 mg daptomycin. One ml provides 5 0 mg of daptomycin after reconstitution w ith 10 ml of sodium chloride 9 mg/ml (0.9 %) solution. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for injection or infusion A pal e yellow to light brown lyophili sed cake or powder. 4. CLINICAL PARTICUL ARS 4.1 THERAPEUTIC INDICATIONS Cubicin is indicated fo r the treatment of t he foll owing infections (see se ctions 4.4 and 5.1). - Adult and paediatric (1 to 17 years of age) patients with c omplicated skin and soft -tissue infections (cSSTI). - Adult patients with right-sided infec tive endocardi tis (RIE) due to Staph ylococcus aureus. It is rec ommended that the decisi on to use daptomyc in should t ake into account t he antibacterial susceptibi lity of the organism and should be based on expert advice. See sections 4. 4 and 5.1. - Adult and paediatric (1 to 17 years of a ge) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use i n bacteraem ia should be assoc iated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated w ith cSSTI. Daptomycin is active ag ainst Gram posit ive ba cteria only (see sec tion 5. 1). In mixed infections where Gram negativ e and/or ce rtain types of ana erobic bacteria are suspect ed, Cubicin should be co-adminis tered with appropriate antibacterial agent (s). Consideration s hould be given to official guidance on the appropriate u se of a ntibacterial agents. 4. Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT C HARA CTERISTICS 2 1. NAME OF THE MEDI CINAL PRODUCT Cubicin 350 mg powder for solution for injection or infusion Cubicin 500 mg powder for solution for in jection or infusion 2. QUALIT ATIVE AND QUANTITATI VE COMPOSITION Cubicin 350 mg powder for solution for i njection or infusion Each vial contains 350 mg daptomycin. One ml provid es 50 mg of dapt omycin after reconstitution with 7 ml of sodium chloride 9 mg/ml (0.9 %) solution. Cubicin 500 mg powder for so lution for injection or infusion Each vial contains 500 mg daptomycin. One ml provides 5 0 mg of daptomycin after reconstitution w ith 10 ml of sodium chloride 9 mg/ml (0.9 %) solution. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for injection or infusion A pal e yellow to light brown lyophili sed cake or powder. 4. CLINICAL PARTICUL ARS 4.1 THERAPEUTIC INDICATIONS Cubicin is indicated fo r the treatment of t he foll owing infections (see se ctions 4.4 and 5.1). - Adult and paediatric (1 to 17 years of age) patients with c omplicated skin and soft -tissue infections (cSSTI). - Adult patients with right-sided infec tive endocardi tis (RIE) due to Staph ylococcus aureus. It is rec ommended that the decisi on to use daptomyc in should t ake into account t he antibacterial susceptibi lity of the organism and should be based on expert advice. See sections 4. 4 and 5.1. - Adult and paediatric (1 to 17 years of a ge) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use i n bacteraem ia should be assoc iated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated w ith cSSTI. Daptomycin is active ag ainst Gram posit ive ba cteria only (see sec tion 5. 1). In mixed infections where Gram negativ e and/or ce rtain types of ana erobic bacteria are suspect ed, Cubicin should be co-adminis tered with appropriate antibacterial agent (s). Consideration s hould be given to official guidance on the appropriate u se of a ntibacterial agents. 4. Aqra d-dokument sħiħ